Xintela

Xintela EBITDA per Employee

EBITDA per Employee of Xintela (XINT.ST) as of Oct 27, 2026.

EBITDA per Employee

-SEK

Last updated:

EBITDA per Employee of Xintela is 2026 - SEK. EBITDA per Employee of Xintela was 2025 - SEK. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Xintela Stock analysis

What does Xintela do? Xintela AB, based in Lund, Skåne, develops pharmaceutical products in the Health Care sector, specifically focusing on regenerative medicine for cartilage damage and osteoarthritis, as well as treatments for glioblastoma brain tumors. The company utilizes therapeutic antibodies and XINMARK, a marker technology using specific proteins to identify stem cells for cartilage development. Listed on 22 March 2016, Xintela operates within biotechnology, targeting innovative therapies in oncology and orthopedics. Xintela is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Xintela stock

On Eulerpool you can find the complete historical development of EBITDA per Employee Xintela since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Xintela historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Xintela

All Key Metrics — Xintela